Lupin has settled all ongoing Hatch-Waxman litigation relating to Memantine tablets, Lupin’s generic version of Forest Laboratories’ Alzheimer disease treatment, Namenda tablets.
Namenda tablet is intended for the treatment of moderate to severe Alzheimer-type dementia. Memantine are a NMDA-receptor antagonist. It works by blocking excess activity of a substance in the brain called glutamate, which may reduce the symptoms associated with Alzheimer disease.
As per the terms of the settlement, Lupin is expected to be licensed under the relevant patents and would be free to commercially launch its generic product in January, 2015, or earlier in certain circumstances.
Previously, Lupin had filed a Paragraph IV certification to US Patent No. 5,061,703, contesting that the patent was invalid or had not been infringed, resulting in the subsequent litigation with Forest.
Nilesh Gupta, group president and executive director at Lupin, said: “The settlement with Forest is in line with us prudently managing our litigation pipeline and creating value for the company.”